Skip to main content

Advertisement

Table 3 Effects of 3 months of 2-g n-3 PUFAs supplementation on metabolic status, inflammatory markers and resolvin D1

From: Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes

Variables Placebo N = 38 n-3 PUFAs N = 36 p value
HbA1c (%)
 Before 7.00 (6.50; 7.50) 7.00 (6.70; 7.48) 0.45
 After 6.80 (6.50; 7.35) 7.10 (6.90; 7.75) 0.06
Insulin (mU/mL)
 Before 22.30 (16.20; 33.63) 20.85 (12.85; 34.80) 0.59
 After 16.80 (12.83; 32.23) 22.35 (13.33; 39.58) 0.72
Peptide C (pmol/mL)
 Before 2.99 (2.10; 4.07) 3.27 (2.70; 4.11) 0.43
 After 2.87 (1.97; 4.03) 3.30 (2.41; 4.64) 0.15
TC (mmol/L)
 Before 3.53 (3.16; 4.21) 3.80 (3.25; 4.63) 0.50
 After 3.78 (3.25; 4.45) 3.50 (3.11; 4.35) 0.53
LDL-C (mmol/L)
 Before 1.84 (1.47; 2.48) 2.07 (1.62; 2.83) 0.51
 After 2.07 (1.71; 2.54) 1.81 (1.44; 2.59) 0.24
HDL-C (mmol/L)
 Before 1.23 (1.04; 1.56) 1.22 (0.90; 1.39) 0.45
 After 1.24 (0.99; 1.47) 1.19 (0.91; 1.56) 0.76
TG (mmol/L)
 Before 1.30 (0.95; 1.62) 1.79 (1.8; 2.41) 0.01
 After 1.41 (1.13; 1.72) 1.48 (0.91; 2.08) 0.69
Leptin (ng/mL)
 Before 5.66 (2.54; 9.14) 3.26 (1.21; 8.09) 0.09
 After 6.14 (3.02; 12.19)* 3.45 (1.35; 8.18) 0.01
Adiponectin (ng/mL)
 Before 4.03 (3.21; 6.35) 3.52 (2.32; 4.06) 0.01
 After 4.19 (3.20; 5.75) 3.26 (2.28;4.42) 0.03
hsCRP (mg/L)
 Before 1.71 (0.72; 3.10) 1.52 (0.76; 2.53) 0.73
 After 1.97 (0.98; 3.13) 1.75 (0.66; 3.73) 0.67
IL-6 (pg/mL)
 Before 2.03 (1.49; 3.32) 1.97 (1.57;2.38) 0.66
 After 1.95 (1.19; 3.76) 2.05 (1.69; 3.43) 0.50
TNF-α (pg/mL)
 Before 1.48 (1.29; 1.72) 1.51 (1.26; 1.84) 0.66
 After 1.47 (1.25; 1.86) 1.46 (1.21; 1.76) 0.73
sICAM-1/CD54 (ng/mL)
 Before 205.87 (169.4;258.7) 222.64 (168.2; 241.2) 0.94
 After 201.88 (168.0; 262.4) 208.27 (178.3; 271.6) 0.74
sVCAM-1/CD106 (ng/mL)
 Before 875.20 (659.8; 1385.0) 1138.2 (818.6; 1604.3) 0.11
 After 832.95 (638.3; 1515.0) 1275.3 (825.9; 1554.9) 0.06
Myeloperoxidase (ng/mL)
 Before 28.80 (18.43; 40.68) 40.46 (20.16; 55.57) 0.15
 After 28.24 (18.56; 44.92) 29.18 (24.21; 48.99) 0.60
RvD1 (pg/mL)
 Before 244.60 (150.1; 457.5) 237.40 (123.40; 469.0) 0.59
 After 232.85 (144.65; 409.4) 184.90 (106.08; 660.6) 0.74
  1. Data shown as number (percentage) for categorical variables and mean (±standard deviation) or median (IQR) for continuous variables
  2. HbA1c glycated hemoglobin, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, hsCRP high-sensitivity C-reactive protein, IL-6 interleukin-6, TNF-α tumor necrosis factor-α, ICAM-1 intercellular adhesion molecule-1, VCAM-1 vascular adhesion molecule-1, RvD1 resolvin D1
  3. * p = 0.01 within the placebo group